You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
International Journal of Molecular Sciences
Download PDF
  • Review
  • Open Access

16 June 2020

A Yeast-Based Model for Hereditary Motor and Sensory Neuropathies: A Simple System for Complex, Heterogeneous Diseases

,
,
,
and
1
Neuromuscular Unit, Mossakowski Medical Research Centre Polish Academy of Sciences, 02-106 Warsaw, Poland
2
Institute of Biochemistry and Biophysics Polish Academy of Sciences, 02-106 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci.2020, 21(12), 4277;https://doi.org/10.3390/ijms21124277
This article belongs to the Special Issue Yeast Models and Molecular Mechanisms of Neurodegenerative Diseases
Version Notes
Order Reprints
Review Reports

Abstract

Charcot–Marie–Tooth (CMT) disease encompasses a group of rare disorders that are characterized by similar clinical manifestations and a high genetic heterogeneity. Such excessive diversity presents many problems. Firstly, it makes a proper genetic diagnosis much more difficult and, even when using the most advanced tools, does not guarantee that the cause of the disease will be revealed. Secondly, the molecular mechanisms underlying the observed symptoms are extremely diverse and are probably different for most of the disease subtypes. Finally, there is no possibility of finding one efficient cure for all, or even the majority of CMT diseases. Every subtype of CMT needs an individual approach backed up by its own research field. Thus, it is little surprise that our knowledge of CMT disease as a whole is selective and therapeutic approaches are limited. There is an urgent need to develop new CMT models to fill the gaps. In this review, we discuss the advantages and disadvantages of yeast as a model system in which to study CMT diseases. We show how this single-cell organism may be used to discriminate between pathogenic variants, to uncover the mechanism of pathogenesis, and to discover new therapies for CMT disease.

1. Introduction

The peripheral neuropathies, also known as polyneuropathies, are a large group of disorders affecting the three types of peripheral nerves: motor, sensory, and autonomic. The clinical presentations of all neuropathies overlap, and the primary causes are numerous and varied. Infectious, immune-mediated, metabolic, toxic, vascular, genetic, and idiopathic forms can all be distinguished from one another. Hereditary neuropathies include Charcot–Marie–Tooth disease (CMT), also known as hereditary motor sensory neuropathy (HMSN); the hereditary motor neuropathies (HMN); the hereditary sensory and autonomic neuropathies (HSAN), also known as hereditary sensory neuropathy (HSN); and small fiber neuropathies (SFN). It is notable that the lines between one class and the next are relative and considered “blurred” or “fluid”. The CMT disease can be classified into several types/subtypes, depending on the mode of inheritance (dominant, recessive), the pattern of the injury (axonal, demyelinating) and the genes involved (more than 100 different genes have been identified so far). Despite this high heterogeneity, the clinical presentation allows for the “classical” CMT phenotype to be distinguished. Typically, the disease begins between the first and second decade of life, with weakening and wasting of the distal muscles, usually of the lower limbs, with accompanying sensory abnormalities. Some patients have skeletal deformities, the most common being pes cavus (a high arched foot). The muscle-wasting and weakness slowly progresses and worsens throughout the patient’s life. In addition to the “classical” CMT symptoms, the patient may also exhibit a wide range of additional symptoms, including hearing impairment, optic atrophy, vocal cord paresis, distal arthrogryposis, and even diaphragmatic weakness [1].
In the late 1960s, the overall prevalence of CMT in the population was estimated as being at the level of 1:2500 [2]. However, the most recent epidemiological studies have shown that there is considerable geographic variation, with a minimum prevalence in Serbia (9.7:100,000), and much higher levels in Norway (1:1250). In general, using different methodologies, the prevalence of CMT has been determined as ranging from 1:5000 to 1:10,000 in European populations [3]. Despite the relatively high prevalence of CMT in some populations, its subtypes belong to the group of rare or even ultra-rare diseases and, like most disorders in this group, suffer from the same problems, namely, verification of mutation pathogenicity, poorly understood molecular mechanisms and a lack of efficient treatments. In this review, we raise the issue of using yeast as a model for studying neuropathies, in particular CMT disease, and present how it may help to overcome these three problematic, but ultimately basic, issues. Yeast systems offer many advantages that are still poorly utilized to investigate neuropathies in general. Many researchers do not realize that yeast may be a convenient model for studying ongoing processes in peripheral nerves diseases. We present the huge potential of this simple, unicellular organism to improve diagnostics, expand the understanding of pathogenesis, and accelerate the development of treatment. The studies of CMT disorder using a yeast model included here have not been summarized in any review to date; hence, we hope that by showing the broad spectrum of possibilities that yeast systems present, it may be more widely adopted as a useful tool in CMT research.

2. Genetic Background of Charcot–Marie–Tooth Disease

CMT disease is characterized by an extreme genetic heterogeneity. To date, more than 1000 mutations have been described in more than 100 genes as causes of different CMT disease types (subtypes) [4]. Familial aggregation of CMT cases was identified at the beginning of the 20th century [5]. Around 70 years later, the first CMT-associated gene and the most common genetic cause of CMT was described (a 1.4 Mb tandem duplication located on chromosome 17p11.2-p12, encompassing the PMP22 gene) [6,7]. The duplication of PMP22, responsible for CMT type 1A (CMT1A), is identified in more than 60% of CMT-affected patients [1]. Point mutations in three other genes—GJB1, MFN2 and MPZ (causing CMTX1, CMT2, and CMT1B, respectively)—are responsible for around 30% of CMT cases [8]. At the opposite end of the spectrum are genes in which mutations have only been identified in isolated CMT families and lineages. This list includes mutations in PRPS1, ATP7A, and IGHMBP2.
Surprisingly, even in the era of next-generation sequencing (NGS), using whole exome sequencing (WES) technology, which enables for testing of all known CMT-causing mutations in a single approach, results in diagnosis for only 45% of CMT disease cases [1]. The relatively low ratio of positively verified CMT cases may be associated with structural variations that are not detectable in routine molecular analysis, expanding the mutation spectrum of existing CMT variants. These structural variations encompass both large translocations (e.g., a 1.35 Mb inversion on chromosome 7q36.3) and relatively small duplications (e.g., 118 kb, 6.25 kb) [9]. However, the list of genes responsible for CMT disease seems to be far from complete. In recent years, additional mutations in genes previously unassociated with CMT disease have been reported in single families [4]. For these small sample groups, the mechanism of pathogenicity associated with these genetic mutations remains unclear. Thus, despite access to powerful genetic tools, such as WES or whole genome sequencing (WGS), a correct and clear diagnosis based on a comprehensive genetic analysis is still not available for many patients.
The distinction between pathogenic and non-pathogenic variants of a disease is a problem for all genetic diseases. Solving this problem is important in order to assess the risk of disease in individual patients and for the development of therapies. The relationship between the gene and the disease can be established by comparing the frequency of rare variants in the patient group compared to the healthy population [10,11]. There are also various computational and experimental methods used to deduce the pathogenicity of rare variants. However, computational methods have the limited predictive potential [12,13,14,15,16,17], and the experimental evaluation of variant function in human cells is difficult, due to inefficient allele replacement methods and the presence of paralogs with overlapping functions. This makes tests in "humanized" model organisms, such as yeast, an attractive alternative.

3. Therapeutic Approaches for Charcot-Marie-Tooth Disorder

The vast majority of experimental therapies are dedicated to the most common CMT subtypes, i.e., CMT1A (PMP22 gene duplication), CMTX1 (GJB1 gene point mutations), CMT1B (MPZ gene mutations) and CMT2A (MFN2 gene mutations), which, together, make up more than 90% of genetically confirmed CMT cases [18]. However, even in these cases, the proposed therapies are not universal. They usually target a single disease mechanism, and are thus dedicated to a specific set of mutations in the associated gene. Gene therapy has also been attempted as a treatment for CMT disease caused by less common mutations, including IGHMBP2 and SH3TC2 [19,20,21]. As the treatment strategies for different types of CMT were described in detail elsewhere [22], below, we summarize the most important information about possible therapies for CMT disorder.
CMT1A, the most common CMT disease subtype, is the result of elevated expression of PMP22. Down-regulation of PMP22 is, therefore, the main therapeutic strategy targeting this disease subtype. Unfortunately, the first attempts to down-regulate PMP22 gene expression in a mouse model (ascorbic acid) and in a transgenic rat model (progesterone receptor antagonists) could not be translated into human clinical trials [23,24,25]. The discovery that a combination of three medications already on the market (baclofen, sorbitol and naltrexone—PXT3003) was able to ameliorate the long-term phenotypical manifestation of peripheral neuropathy in a CMT1A rat model was a significant step forward (reviewed in [26]). Recently, encouraging news in relation to the Phase III trial of PXT3003 was reported [27]. Another promising pre-clinical therapeutic for patients carrying the CMT1A mutation is ADX71441 (a positive allosteric modulator of GABAB receptors) [28], which was approved for phase I clinical trials for other diseases [29]. In addition, the use of antisense oligonucleotides (ASOs) appears to be a good strategy for the suppression of PMP22 mRNA levels [30]. Nevertheless, it is notable that a variety of missense (amino acid substitutions), nonsense (premature termination due to stop codons), and frameshift mutations have also been described in PMP22, some of them causing more severe phenotypes. These mutations result in a different, not yet fully elucidated, pathogenic mechanism [31] that will require different therapeutic strategies.
The second most common form of CMT disease, CMTX1, is caused by mutations within the GJB1 gene, and seems to be an optimal candidate for gene replacement therapy, due to the small size of the GJB1 gene and the loss-of-function observed for the majority of GJB1 mutations [32,33]. The treatment strategy for the next most common type of CMT, CMT1B, which is caused by mutations in MPZ, is mainly focused on relieving the effects of accumulated mutant forms of the protein in the endoplasmic reticulum (ER). However, this mechanism is not observed in all MPZ mutations, and some may manifest in different manners [31]. It was shown that curcumin was able to release MPZ mutant proteins from the ER to the cytoplasm and cause a significant decrease in apoptosis in HeLa cells [34]. Curcumin also demonstrated positive results in a CMT1B mouse model [35,36]. Sephin1 (a selective inhibitor of a holophosphatase), which attenuates stress resulting from misfolded proteins, also had a beneficial effect [37]. Finally, for CMT2A disease caused by mutations in the MFN2 gene (encoding Mitofusin 2), abnormal mitochondrial trafficking has been reported for at least some mutations. In recent studies, mitofusin agonists have been shown to normalize mitochondrial pathology in the sciatic nerves of MFN2 Thr105Met mice [38].
Despite numerous attempts, no single effective therapeutic for CMT disorders has been registered on the market to date. The vast majority of CMT subtypes and mutations in “common” CMT genes with no “classical” (or an unknown) pathogenic mechanism have not been the subject of research for therapeutic approaches [39]. This state is a result of major barriers to research—including diverse molecular mechanisms for most CMT subtypes (even for different mutations in the same gene)—a lack of knowledge relating to the pathophysiology of specific variants, a deficiency of good disease models, and problems with translating results from animal models into humans. In this context, new models with which to identify new drugs may help to fill the gaps in available CMT therapies.

4. Studies of CMT in Yeast-Based Models for Human Genes with Yeast Orthologs

The simplicity of yeast is both its principle advantage and disadvantage as a model system. On the one hand, yeast provides an easy, cheap, and rapid platform for conducting research. On the other hand, are we truly able to use it to study processes in very complex systems such as neurons? Can yeast really help to solve the problems that neurogenetics faces: the unknown pathogenicity of rare sequence variants; unclear disease mechanisms; and a lack of effective therapies for patients? It has been shown that yeast can help in all of these cases. In this section, we will present the commonalities between a single-celled yeast and very sophisticated neurons, and how we can exploit these.
Although yeast and humans are separated by a billion years of evolution, a pairwise comparison of genes between these two species reveals more than 2041 groups of orthologs, representing 2386 yeast genes and 3673 human genes [40]. Moreover, there are more than 1000 functional complementation pairs, where a gene from one species can functionally replace (complement) its ortholog in the other [41]. This clearly indicates a significant conservation of function between such distant species, which opens a great number of research possibilities to explore. In the past 30 years, more than 400 yeast genes have been used to study their human counterparts [42]. Whether a human gene will complement mutations of its yeast ortholog cannot be confidently predicted based on the sequence alone [43]. Data related to experimental cross-species complementation are collected and are easy to extract from an open database (for details see [41]). The broad spectrum of possibilities of how to create and utilize yeast as a human model for diseases has been described elsewhere [42,44]. Here, we would like to highlight efficient neuropathy yeast-based models.
The CMT disease consists of a group of disorders displaying high genetic heterogeneity. If we looked at the list of genes associated with neuropathies (Table 1 and Table 2), with a particular focus on the function of proteins that they encode, we notice that these proteins occur in a diverse range of cellular pathways and processes. This ranges from the most common of processes, for example, translation (aminoacyl-transfer RNA (tRNA) synthetases), to highly specialized processes such as myelin sheath formation. It is not possible to study the formation of myelin using yeast, but it may be a good model to describe pathogenic mechanisms in more basic processes.
Table 1. Human Genes Associated with Neuropathies and Their Yeast Orthologs.
Table 2. Human Genes Associated with Neuropathies with No Yeast Orthologs.
Looking at Table 1 and Table 2, of the more than 170 genes involved in various neuropathies, 60 have orthologs in yeast cells (Table 1 and Figure 1).
Figure 1. Scheme showing the localization of selected proteins, in which mutations have been associated with hereditary peripheral neuropathies in a human nerve cell and a yeast Saccharomyces cerevisiae cell. The violet color indicates human proteins complementing mutations in yeast proteins, marked in red; green indicates human proteins possessing orthologs in yeast S. cerevisiae that are marked orange.
Some of these genes are so well conserved that even human genes may, at least in part, complement a lack of native yeast orthologs (Table 1). This gives a wide range of possibilities to model and study the neuropathy-associated mutations in yeast cells, which has advantages over other more complex models in terms of its low cost, growth rate, and genetic tractability. However, this opportunity is usually not fully exploited. In most cases, yeast is used only sporadically and to investigate one narrow aspect of a disease-associated mutation. Meanwhile, similar to other rare disorders, yeast-based neuropathy models may, at least partially, solve three of the major problems faced by researchers (Figure 2).
Figure 2. Yeast as a system to evaluate functional effects of human genetic variations. The coding part of a human gene (cDNA) is inserted under a yeast regulatory sequence and transformed into yeast cells, where it is expressed. The resulting protein interacts with yeast cellular components (proteins, RNAs, lipids, etc.) and affects the cell physiology, leading to the selected phenotypes which may be monitored. The system presented may be used to test unknown sequence variants to improve diagnosis, or for screening drug candidates and investigating the molecular mechanisms of pathogenicity to develop future experimental therapies.
The first problem is the significance of rare sequence variants found in patients. As mentioned above, in the current era of NGS, several rare alleles are often identified in individual patients, but their impact on human health is usually poorly understood. This is one of the reasons for prolonged and incomplete diagnoses. There is an urgent need to develop a fast, cheap and reproducible system to test the pathogenicity of identified sequence variants. Yeast has been presented as a good platform for the study of aminoacylation activity, and, thus, the possible pathogenicity of human aminoacyl-transfer RNA (tRNA) synthetases (aaRSs) encoded by ARS genes [68]. AaRSs are key enzymes that catalyze the first reaction in protein biosynthesis, charging tRNAs with their cognate amino acids. To date, mutations in six ARS genes have been associated with CMT disorders (GARS, YARS, AARS, MARS, HARS, and WARS, encoding glycyl- tyrosyl- alanyl-, methionyl-, histidyl-, tryptophanyl-RS, respectively) [53,69,70,71,72,73]. It has been shown that human orthologs can complement the lethality of the deletion of the alanyl-, glycyl-, histidyl-, tyrosyl-RS genes (ALA1, GRS1, HTS1, TYS1, respectively) in yeasts and restore the growth of these cells (see Table 1). The other two human ARS genes associated with CMT (MARS and WARS) possess yeast orthologs (MES1 and WRS1, respectively), which allows researchers to model the mutations found in patients in the corresponding yeast genes. Testing newly identified rare variants in yeast not only allows the identification of loss-of-function (functional null; hypomorphic) alleles but can also reveal gain-of-function (i.e., hypermorphic) alleles [45,73]. Even though a human full-length wild-type WARS failed to complement a wrs1 deficiency in yeast cells, a mutant WARS incorporating a H257R substitution could partially complement the lack of WRS1, which implies that H257R substitution may change the structure of human tryptophanyl-RS [73].
Another example of using a yeast-based system to investigate rare sequence variants is the study of mutations in the POLG gene, which encodes the catalytic subunit of mtDNA polymerase γ. Pathological mutations in this gene are usually associated with severe mitochondrial disorders, but may also manifest as an isolated neuropathy [74]. Yeast is a suitable model organism for the study of alleles resulting in severe oxygen and/or respiration impairment and mitochondrial dysfunction, due to its ability to survive without oxidative phosphorylation. Comparable phenotypes (the harmful effects observed in yeast reproduce the severity of the phenotypes in humans), the possibility to study variants in heteroallelic states, and easy and fast analysis make budding yeast an excellent model for testing mutations in POLG. In POLG-associated diseases, yeast has enabled researchers to distinguish pathogenic mutations from other single-nucleotide polymorphisms; to show that some polymorphisms may act as phenotypic modifiers; and has demonstrated that certain mutations are not the only cause of a pathology, highlighting the need for further genetic analysis [75,76,77,78,79,80,81].
The second problem is a deficiency or complete lack of knowledge related to the molecular mechanisms underlying the pathogenicity of mutations. Information about the cellular processes that trigger pathogenic changes and ultimately lead to the symptoms observed in patients may provide clues for the production of effective therapeutics. It may also reveal the possible toxicity of the drugs used and which drugs should be avoided when treating specific patients. It may also enable recommendations to be made for lifestyle changes to improve the quality of life and slow the disease’s progression. An example of using yeast to learn about the mechanism of pathogenicity of a specific mutation is the study of the human gene MFN2 encoding Mitofusin 2. Mutations in MFN2 result in the most frequent axonal form of CMT (CMT2A) [82]. Mitofusin 2 represents a key player in mitochondrial fusion, trafficking, turnover and the formation of contacts with other organelles [83]. Yeast mitofusin, Fzo1, was used to study the consequences of CMT2A mutations associated with the human MFN2 gene. It was shown that one mutation in particular (causing a substitution analogous to the I213T substitution in Mfn2) is highly deleterious for protein function and stability. Other mutations had variable effects, causing either no phenotype, or a subtle alteration of mitochondrial morphology [84]. The study of Mfn2 function is also of importance because mitofusins belong to the group of proteins important for the formation, regulation, and function of endoplasmic reticulum (ER) and mitochondrial membrane contact sites (MCSs), called mitochondria-associated membranes (MAMs). MCSs are structures where membranes of different organelles are close and connected by a proteinaceous tether but do not fuse. The genes affecting homeostasis in MAMs are over-represented in the group of genes causing several hereditary neurodegenerative disorders, such as Alzheimer’s disease [85,86,87,88] and Chorea-acanthocythosis [89]. This is because MCSs are involved in various processes, including mitochondrial dynamics (fusion, fission), lipids metabolism, autophagy, cell survival, energy metabolism, calcium homeostasis, and protein folding [90,91,92]. In the group of genes causing CMT disorders, besides Mfn2, there are other proteins with and without orthologs in yeast, which take part in processes at MAMs, such as VAPB, Opa1, or GDAP1 [93]. Studies on the function of one MCSs component may help uncover the role of MCSs in the development of several other neurodegenerative diseases. More details about the role of MAMs in neurodegeneration can be found in other reviews [85,86,87,88].
The third and final challenge, facing not only neuropathies but all rare diseases, is a lack of therapies. This problem was more specifically described in the Section 3. Yeast may also serve as a rapid and cheap platform with which to screen potentially active compounds, and for a detailed analysis of the cellular effects of drugs (see Section 6).

5. Studies of CMT for Human Genes Lacking Orthologs in the Yeast Model

The most simple yeast-based neuropathy models are based on the homology between human and yeast genes. However, even in the absence of clear orthologs, yeast may still be used to study the three problematic areas for rare diseases identified in Section 4.
The strategy that allows for this is based on the belief that yeast and the cells of higher organisms are built and function according to the same principles. Thus, human proteins may still be able to modulate essential cellular pathways in yeast. This rule has been shown in the case of yeast-based studies of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Here, the heterologous expression of pathological variants of aβ-peptide, α-synuclein or poly-Q repeats of different lengths in the yeast allowed researchers to dissect the molecular mechanisms underlying the pathology of mutant proteins, identify potential drug targets and select active compounds by screening the available drug libraries [94,95,96,97,98]. Similarly, in the case of genes whose mutations lead to CMT diseases and which have no orthologs (Table 2), their expression in yeast may still affect cells and limit their growth.
This strategy, testing the activity of a human protein without an ortholog in yeast, has already been used to study neuropathy associated with mutations in the GDAP1 gene encoding ganglyoside induced differentiation associated protein 1. Although the production of this protein does not affect the growth of wild-type yeast cells, it has manifestations at the molecular level, as shown in two different studies [99,100]. In both studies, the effect of heterologous GDAP1 expression in the wild-type and different yeast mutants was tested. Based on the observation that increased expression of GDAP1 in COS-7 cells results in mitochondrial fragmentation, which is probably due to interference with the mechanism of mitochondrial fission, the influence on yeast mitochondria morphology was investigated [99,100]. The expression of GDAP1 either did not affect yeast mitochondria morphology [99], or caused increased fragmentation of the mitochondria, depending on the specific experimental procedures [100], and also changed mtDNA maintenance [100]. GDAP1 expression in the fis1Δ mutant, defective for mitochondrial fission and for G2/M progression during the cell cycle, did not eliminate the mitochondrial fission defect, but reversed the cell cycle delay phenotype of this mutant [99]. Although the results obtained did not define the molecular function of the GDAP1 protein, they indicate the pathway for further research. Moreover, finding a clear phenotype allowed for further testing of the effect of pathogenic GDAP1 gene missense variants. Since all the investigated variants did not reverse the cell cycle delay phenotype of a fis1Δ mutant, it suggests that this phenotype can be used to study new GDAP1 variants and distinguish pathogenic from non-pathogenic alleles identified in patients during the diagnostic process. However, it is not possible to differentiate between variants in terms of the strength of the clinical symptoms induced.
A more functional system with which to evaluate the pathogenicity of GDAP1 gene mutations was reported in our previous study [100]. In this case, the csg2Δ mutant was used with the deletion of a gene required for mannosylation of inositolphosphorylceramide. The sensitivities of the csg2Δ strain to stress conditions, the presence of tunicamycin and high concentrations of calcium ions (Ca2+) were all suppressed by the expression of the wild-type GDAP1 allele, but not by GDAP1 variants encoding proteins that lost the ability to correctly localize to the mitochondria. Different GDAP1 variants (point mutants) exhibited differing abilities to suppress these phenotypes. This system, in addition to enabling testing of the pathogenicity of GDAP1 alleles isolated from patients, should also allow for their classification in terms of the severity of the resulting clinical phenotypes.
These two working systems show that GDAP1 functionality can be assessed in yeast cells even though yeast has no functional orthologs. This is due to the fact that they participate in conserved cellular processes (Table 2) and, consequently, there are functional orthologs of their partner proteins (Figure 2). Based on this principle, it is possible to build additional yeast-based models for other genes that are involved in CMT disease, but do not have yeast orthologs. An example of this is the human gene MTMR2 coding for Myotubularin 2-related protein, a member of the myotubularin family of phosphoinositide lipid phosphatases. Myotubularin 2 functionally interacts with the phosphoinositide 5-phosphatase protein FIG4, amongst other proteins in Schwann cells and in neurons [101]. Mutations in the FIG4 gene, similar to in MTRM2, are described as resulting in CMT disease. The human FIG4 has a yeast ortholog, making it is possible to build a model to directly study FIG4, and to indirectly test MTMR2 function in a yeast model.
Another possible use of the preservation of biochemical pathways is associated with the CMT subtype, caused by mutations in the MPZ gene. Some mutant MPZ proteins are retained in the ER, where their accumulation triggers an induction of the unfolded protein response (UPR). Although the downregulation of UPR has already been shown to have a positive effect in CMT1B, the problem associated with distinguishing between pathogenic and non-pathogenic variants and the subsequent search for mechanisms of pathogenicity remains. In a case of mutations in the MPZ gene, a yeast model can be used because of the conservation of biochemical pathways.
As a result of UPR induction in mammalian cells, the eIF2 kinases PERK and GCN2 are activated and phosphorylate the translation initiation factor 2 (eIF2a). This leads to the synthesis of transcription factor ATF4 and increased production of the CHOP protein. The induction of this response has been shown to cause demyelination in CMT1B. Depletion of CHOP or its subsequent target, Gadd34, improves myelination [102]. The mammalian signaling pathway leading to eIF2a phosphorylation is homologous to the well-studied general control response in yeast, in which phosphorylation of eIF2a activates genes involved in amino acid biosynthesis. Thus, mammalian cells use a conserved pathway to regulate gene expression in response to various stresses [103]. Therefore, it is possible to use yeast to study the pathogenicity of mutations by monitoring the effects caused by the presence of MPZ protein variants at the molecular level.
Finally, with models such as those described above, we can study the pathogenicity of variants and mechanisms of pathogenesis and use them to find therapies by searching libraries of small molecules. This experimental approach could and should be far more widely applied to the investigation of CMT diseases.

6. Repositioning of Drugs in Hereditary Neuropathies

In the case of common disorders, effective medicines can be found and tested in clinical trials involving thousands of patients, but for rare and ultra-rare diseases, the classical approaches to drug discovery are very difficult to follow. This is due to the small number of patients and the lack of economic justification for pharmaceutical companies to engage large resources in research that will not be profitable for them.
This problem applies to CMT disease, which can be classified as a rare or even ultra-rare disease. In such cases, one favorable solution is a drug repurposing strategy. Drug repurposing (also known as repositioning, reprofiling, rediscovering or redirecting) may be defined as developing new uses for a drug beyond its original intended use or initially approved use. The best example of drug repurposing is that of chlorpromazine. In 1950, chlorpromazine, synthesized as a potential antimalarial drug, was administered to patients before surgery. Due to its unexpected sedative effects, a weak anti-malarial drug has become a powerful medicine used in both psychiatry (acute mania) and neurology (chorea, epilepsy, muscle spasms, etc.) [104]. Drug repositioning radically reduces the cost of clinical trials, prevents the withdrawal of a drug from the market due to low interest, and usually allows well-known and cheap pharmaceuticals to be selected as the preferred option. This latter feature is especially important when developing therapies for rare disorders, as the alternatives (e.g., gene therapy or cell therapy) are extremely expensive.
Yeast models have great potential to be used as a platform for the screening of drugs libraries to obtain preliminary results. Such models benefit from a fast turnaround, low cost, and easy testing. Yeast models have been successfully used to search for active compounds against mitochondrial diseases [105,106,107], central nervous system diseases [108], and copper-deficiency disorders [109]. Thus, it seems reasonable that, for peripheral neuropathies, yeast models may also be applied and allow for drug repositioning. Nearly a third of human genes involved in the pathogenesis of CMT have yeast orthologs, making it relatively easy to create yeast-based models. For the other cases, there is the possibility of finding a convenient, easy to quantify phenotype (e.g., a toxic effect associated with the expression of gene variants), which may be used for drug screening. The other option is the use of phenologs, which are the phenotype-level equivalent of gene orthologs. Two sets of deeply conserved genes between extremely evolutionary divergent organisms, i.e., yeast and humans, may be manifested in the different molecular contexts as two dissimilar phenotypes. For example, cell-wall maintenance in yeast and vascular growth in human are phenologous processes: they share the same genes conserved between yeast and human. The failure of the equivalent genes will lead to disturbed angiogenesis in humans and reduced cell-wall maintenance in yeast. Using this logic, thiobendazole—marketed as an antifungal drug—would also act as an angiogenesis inhibitor in humans [110,111]. Similarly, phenologous processes may also be used for drug selection in CMT disease.
The repurposing strategy may be key to finding therapies, especially for very rare subtypes of CMT. To date, this approach has been poorly used for CMT diseases. Only a few CMT genes and their mutations (AARS, ATP7A, GARS, HARS, HINT1) have been modeled in yeast so far, and any have not been used for drug repurposing, despite the systems being ready to test collections of highly bioavailable drugs of known toxicity in models to confirm their action and to select the effective dose.

7. Outlook

Rapidly developing technologies provide ever-improving diagnostics, pathology monitoring and therapies. However, they also reveal the limitations of current approaches and “black holes” in our knowledge. Returning to more basic, simple models may be a key for further research regarding different, and especially very rare, neuropathies. Included in this work are examples that clearly indicate that yeast models have a great potential to serve as neuropathic models. These models are currently underused. Yeast models are a promising tool for the determination of the pathogenicity of newly discovered rare sequence variants and their influence on the progression of a disease. In addition, they may also provide an excellent platform for studying the molecular and cellular background of pathogenesis and offer a cheap, easy, and fast system for the high-throughput screening of genetic and chemical suppressors that would give rise to potential therapeutics. Yeast models have advantages over other models in terms of cost, ease of growth and use, and the facilities necessary to implement them. They could be used as a convenient tool in almost all laboratories, and we hope that they will continue to be developed to support the study of more hereditary neuropathies.

Funding

This research was funded by National Science Centre Poland, grant number UMO-2016/23/B/NZ3/02035.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Pipis, M.; Rossor, A.M.; Laura, M.; Reilly, M.M. Next-generation sequencing in Charcot-Marie-Tooth disease: Opportunities and challenges. Nat. Rev. Neurol. 2019, 15, 644–656. [Google Scholar] [CrossRef] [PubMed]
  2. Skre, H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin. Genet. 1974, 6, 98–118. [Google Scholar] [CrossRef] [PubMed]
  3. Barreto, L.C.L.S.; Oliveira, F.S.; Nunes, P.S.; Costa, I.M.P.D.F.; Garcez, C.A.; Goes, G.M.; Neves, E.L.A.; Quintans, J.S.; Araújo, A.A.D.S. Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review. Neuroepidemiology 2016, 46, 157–165. [Google Scholar] [CrossRef] [PubMed]
  4. Laurá, M.; Pipis, M.; Rossor, A.M.; Reilly, M.M. Charcot-Marie-Tooth disease and related disorders. Curr. Opin. Neurol. 2019, 32, 641–650. [Google Scholar] [CrossRef]
  5. Roussy, G.; Levy, G. Sept cas d’une maladie familiale particuliere: Troubles de la marche, pieds bots et aréflexie tendineuse généralisée, avec, accessoirement, légere maladresse des mains. Rev. Neurol. (Paris) 1926, 1, 427–450. [Google Scholar]
  6. Lupski, J.R.; Oca-Luna, R.M.; Slaugenhaupt, S.; Pentao, L.; Guzzetta, V.; Trask, B.J.; Saucedo-Cardenas, O.; Barker, D.F.; Killian, J.M.; Garcia, C.A.; et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991, 66, 219–232. [Google Scholar] [CrossRef]
  7. Timmerman, V.; Nelis, E.; Van Hul, W.; Nieuwenhuijsen, B.; Chen, K.; Wang, S.; Ben Othman, K.; Cullen, B.; Leach, R.; Hanemann, C.O.; et al. The peripheral myelin protein gene PMP–22 is contained within the Charcot–Marie–Tooth disease type 1A duplication. Nat. Genet. 1992, 1, 171–175. [Google Scholar] [CrossRef]
  8. Fridman, V.; Bundy, B.; Reilly, M.M.; Pareyson, D.; Bacon, C.; Burns, J.; Day, J.; Feely, S.; Finkel, R.S.; Grider, T.; et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: A cross-sectional analysis. J. Neurol. Neurosurg. Psychiatry 2014, 86, 873–878. [Google Scholar] [CrossRef]
  9. Cutrupi, A.N.; Brewer, M.H.; Nicholson, G.A.; Kennerson, M.L. Structural variations causing inherited peripheral neuropathies: A paradigm for understanding genomic organization, chromatin interactions, and gene dysregulation. Mol. Genet. Genom. Med. 2018, 6, 422–433. [Google Scholar] [CrossRef]
  10. MacArthur, D.G.; Manolio, T.A.; Dimmock, D.; Rehm, H.L.; Shendure, J.; Abecasis, G.R.; Adams, D.R.; Altman, R.B.; Antonarakis, S.E.; Ashley, E.A.; et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014, 508, 469–476. [Google Scholar] [CrossRef]
  11. Purcell, S.M.; Moran, J.; Fromer, M.; Ruderfer, D.M.; Solovieff, N.; Roussos, P.; O’Dushlaine, C.; Chambert, K.; Bergen, S.E.; Kahler, A.; et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506, 185–190. [Google Scholar] [CrossRef] [PubMed]
  12. Mathe, E.; Olivier, M.; Kato, S.; Ishioka, C.; Hainaut, P.; Tavtigian, S.V. Computational approaches for predicting the biological effect of p53 missense mutations: A comparison of three sequence analysis based methods. Nucleic Acids Res. 2006, 34, 1317–1325. [Google Scholar] [CrossRef]
  13. Chan, P.A.; Duraisamy, S.; Miller, P.J.; Newell, J.A.; McBride, C.; Bond, J.P.; Raevaara, T.; Ollila, S.; Nyström, M.; Grimm, A.J.; et al. Interpreting missense variants: Comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum. Mutat. 2007, 28, 683–693. [Google Scholar] [CrossRef] [PubMed]
  14. Cline, M.S.; Karchin, R. Using bioinformatics to predict the functional impact of SNVs. Bioinformatics 2010, 27, 441–448. [Google Scholar] [CrossRef] [PubMed]
  15. Thusberg, J.; Olatubosun, A.; Vihinen, M. Performance of mutation pathogenicity prediction methods on missense variants. Hum. Mutat. 2011, 32, 358–368. [Google Scholar] [CrossRef]
  16. Castellana, S.; Mazza, T. Congruency in the prediction of pathogenic missense mutations: State-of-the-art web-based tools. Briefings Bioinform. 2013, 14, 448–459. [Google Scholar] [CrossRef] [PubMed]
  17. Froussios, K.; Iliopoulos, C.; Schlitt, T.; Simpson, M.A. Predicting the functional consequences of non-synonymous DNA sequence variants—Evaluation of bioinformatics tools and development of a consensus strategy. Genomics 2013, 102, 223–228. [Google Scholar] [CrossRef]
  18. Saporta, A.S.; Sottile, S.L.; Miller, L.J.; Feely, S.M.; Siskind, C.E.; Shy, M.E. Charcot-marie-tooth disease subtypes and genetic testing strategies. Ann. Neurol. 2011, 69, 22–33. [Google Scholar] [CrossRef]
  19. Nizzardo, M.; Simone, C.; Rizzo, F.; Salani, S.; Dametti, S.; Rinchetti, P.; Del Bo, R.; Foust, K.; Kaspar, B.K.; Bresolin, N.; et al. Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Sci. Adv. 2015, 1, e1500078. [Google Scholar] [CrossRef]
  20. Shababi, M.; Feng, Z.; Villalon, E.; Sibigtroth, C.M.; Osman, E.; Miller, M.R.; Williams-Simon, P.A.; Lombardi, A.; Sass, T.H.; Atkinson, A.K.; et al. Rescue of a Mouse Model of Spinal Muscular Atrophy With Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent. Mol. Ther. 2016, 24, 855–866. [Google Scholar] [CrossRef]
  21. Schiza, N.; Georgiou, E.; Kagiava, A.; Médard, J.-J.; Richter, J.; Tryfonos, C.; Sargiannidou, I.; Heslegrave, A.J.; Rossor, A.M.; Zetterberg, H.; et al. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy. Brain 2019, 142, 1227–1241. [Google Scholar] [CrossRef] [PubMed]
  22. Jerath, N.U.; Shy, M.E. Hereditary motor and sensory neuropathies: Understanding molecular pathogenesis could lead to future treatment strategies. Biochim. Biophys. Acta 2015, 1852, 667–678. [Google Scholar] [CrossRef] [PubMed]
  23. Passage, E.; Norreel, J.C.; Noack-Fraissignes, P.; Sanguedolce, V.; Pizant, J.; Thirion, X.; Robaglia-Schlupp, A.; Pellissier, J.F.; Fontes, M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat. Med. 2004, 10, 396–401. [Google Scholar] [CrossRef]
  24. Zu Hörste, G.M.; Prukop, T.; Liebetanz, D.; Möbius, W.; Nave, K.-A.; Sereda, M.W. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann. Neurol. 2007, 61, 61–72. [Google Scholar] [CrossRef]
  25. Pareyson, D.; Reilly, M.M.; Schenone, A.; Fabrizi, G.M.; Cavallaro, T.; Santoro, L.; Vita, G.; Quattrone, A.; Padua, L.; Gemignani, F.; et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): A double-blind randomised trial. Lancet Neurol. 2011, 10, 320–328. [Google Scholar] [CrossRef]
  26. Kiepura, A.J.; Kochański, A. Charcot-Marie-Tooth type 1A drug therapies: Role of adenylyl cyclase activity and G-protein coupled receptors in disease pathomechanism. Acta Neurobiol. Exp. 2018, 78, 198–209. [Google Scholar] [CrossRef]
  27. PXT3003 Improves Clinical Outcomes and Stabilizes Disease Progression in CMT1A Patients, Extension Study Shows. Available online: https://charcot-marie-toothnews.com/2020/01/17/pxt3003-continues-to-improve-clinical-outcomes-and-stabilize-disease-progression-in-cmt1a-patients/2020 (accessed on 12 May 2020).
  28. Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease. 2020. Available online: https://www.globenewswire.com/fr/news-release/2013/01/07/1591975/0/en/Addex-Announces-Positive-Data-with-ADX71441-in-a-Pre-Clinical-Transgenic-Model-of-Charcot-Marie-Tooth-1A-Disease.html (accessed on 12 May 2020).
  29. Kalinichev, M.; Girard, F.; Haddouk, H.; Rouillier, M.; Riguet, E.; Royer-Urios, I.; Mutel, V.; Lütjens, R.; Poli, S. The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity. Neuropharmacology 2017, 114, 34–47. [Google Scholar] [CrossRef]
  30. Zhao, H.; Damle, S.; Ikeda-Lee, K.; Kuntz, S.; Li, J.; Mohan, A.; Kim, A.; Hung, G.; Scheideler, M.A.; Scherer, S.S.; et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J. Clin. Investig. 2017, 128, 359–368. [Google Scholar] [CrossRef]
  31. Scherer, S.S.; Wrabetz, L. Molecular mechanisms of inherited demyelinating neuropathies. Glia 2008, 56, 1578–1589. [Google Scholar] [CrossRef] [PubMed]
  32. Scherer, S.S.; Xu, Y.-T.; Messing, A.; Willecke, K.; Fischbeck, K.H.; Jeng, L.J.B. Transgenic Expression of Human Connexin32 in Myelinating Schwann Cells Prevents Demyelination in Connexin32-Null Mice. J. Neurosci. 2005, 25, 1550–1559. [Google Scholar] [CrossRef] [PubMed]
  33. Kagiava, A.; Sargiannidou, I.; Theophilidis, G.; Karaiskos, C.; Richter, J.; Bashiardes, S.; Schiza, N.; Nearchou, M.; Christodoulou, C.; Scherer, S.S.; et al. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. Proc. Natl. Acad. Sci. USA 2016, 113, E2421–E2429. [Google Scholar] [CrossRef]
  34. Khajavi, M.; Inoue, K.; Wiszniewski, W.; Ohyama, T.; Snipes, G.J.; Lupski, J.R. Curcumin Treatment Abrogates Endoplasmic Reticulum Retention and Aggregation-Induced Apoptosis Associated with Neuropathy-Causing Myelin Protein Zero-Truncating Mutants. Am. J. Hum. Genet. 2005, 77, 841–850. [Google Scholar] [CrossRef][Green Version]
  35. Patzkó, A.; Bai, Y.; Saporta, M.A.; Katona, I.; Wu, X.; Vizzuso, M.; Feltri, M.L.; Wang, S.; Dillon, L.; Kamholz, J.; et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012, 135, 3551–3566. [Google Scholar] [CrossRef] [PubMed]
  36. Bai, Y.; Patzkó, A.; Shy, M.E. Unfolded protein response, treatment and CMT1B. Rare Dis. 2013, 1, e24049. [Google Scholar] [CrossRef] [PubMed][Green Version]
  37. Das, I.; Krzyzosiak, A.; Schneider, K.; Wrabetz, L.; D’Antonio, M.; Barry, N.; Sigurdardottir, A.G.; Bertolotti, A. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 2015, 348, 239–242. [Google Scholar] [CrossRef] [PubMed]
  38. Rocha, A.G.; Franco, A.; Krezel, A.M.; Rumsey, J.M.; Alberti, J.M.; Knight, W.C.; Biris, N.; Zacharioudakis, E.; Janetka, J.W.; Baloh, R.H.; et al. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science 2018, 360, 336–341. [Google Scholar] [CrossRef] [PubMed]
  39. Morena, J.; Gupta, A.; Hoyle, J.C. Charcot-Marie-Tooth: From Molecules to Therapy. Int. J. Mol. Sci. 2019, 20, 3419. [Google Scholar] [CrossRef] [PubMed]
  40. Sonnhammer, E.; Östlund, G. InParanoid 8: Orthology analysis between 273 proteomes, mostly eukaryotic. Nucleic Acids Res. 2014, 43, D234–D239. [Google Scholar] [CrossRef]
  41. Skrzypek, M.S.; Nash, R.S.; Wong, E.D.; MacPherson, K.A.; Hellerstedt, S.T.; Engel, S.R.; Karra, K.; Weng, S.; Sheppard, T.K.; Binkley, G.; et al. Saccharomyces genome database informs human biology. Nucleic Acids Res. 2018, 46, D736–D742. [Google Scholar] [CrossRef] [PubMed]
  42. Laurent, J.M.; Young, J.H.; Kachroo, A.H.; Salemi, M. Efforts to make and apply humanized yeast. Brief. Funct. Genom. 2015, 15, 155–163. [Google Scholar] [CrossRef] [PubMed]
  43. Sun, S.; Yang, F.; Tan, G.; Costanzo, M.; Oughtred, R.; Hirschman, J.; Theesfeld, C.L.; Bansal, P.; Sahni, N.; Yi, S.; et al. An extended set of yeast-based functional assays accurately identifies human disease mutations. Genome Res. 2016, 26, 670–680. [Google Scholar] [CrossRef] [PubMed]
  44. Dunham, M.J.; Fowler, D.M. Contemporary, yeast-based approaches to understanding human genetic variation. Curr. Opin. Genet. Dev. 2013, 23, 658–664. [Google Scholar] [CrossRef] [PubMed]
  45. Weterman, M.A.J.; Kuo, M.; Kenter, S.B.; Gordillo, S.; Karjosukarso, D.W.; Takase, R.; Bronk, M.; Oprescu, S.; Van Ruissen, F.; Witteveen, R.J.W.; et al. Hypermorphic and hypomorphic AARS alleles in patients with CMT2N expand clinical and molecular heterogeneities. Hum. Mol. Genet. 2018, 27, 4036–4050. [Google Scholar] [CrossRef] [PubMed]
  46. Ripmaster, T.L.; Shiba, K.; Schimmel, P. Wide cross-species aminoacyl-tRNA synthetase replacement in vivo: Yeast cytoplasmic alanine enzyme replaced by human polymyositis serum antigen. Proc. Natl. Acad. Sci. USA 1995, 92, 4932–4936. [Google Scholar] [CrossRef]
  47. Payne, A.S.; Gitlin, J.D. Functional Expression of the Menkes Disease Protein Reveals Common Biochemical Mechanisms Among the Copper-transporting P-type ATPases. J. Biol. Chem. 1998, 273, 3765–3770. [Google Scholar] [CrossRef]
  48. Wang, C.-W.; Miao, Y.-H.; Chang, Y.-S. Control of lipid droplet size in budding yeast requires the collaboration between Fld1 and Ldb16. J. Cell Sci. 2014, 127, 1214–1228. [Google Scholar] [CrossRef]
  49. Glerum, D.M.; Tzagoloff, A. Isolation of a human cDNA for heme A:farnesyltransferase by functional complementation of a yeast cox10 mutant. Proc. Natl. Acad. Sci. USA 1994, 91, 8452–8456. [Google Scholar] [CrossRef]
  50. Valnot, I.; Von Kleist-Retzow, J.-C.; Barrientos, A.; Gorbatyuk, M.S.; Taanman, J.-W.; Mehaye, B.; Rustin, P.; Tzagoloff, A.; Munnich, A.; Rötig, A. A mutation in the human heme A:farnesyltransferase gene (COX10 ) causes cytochrome c oxidase deficiency. Hum. Mol. Genet. 2000, 9, 1245–1249. [Google Scholar] [CrossRef]
  51. Cavadini, P.; Gellera, C.; Patel, P.; Isaya, G. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum. Mol. Genet. 2000, 9, 2523–2530. [Google Scholar] [CrossRef]
  52. Chien, C.-I.; Chen, Y.-W.; Wu, Y.-H.; Chang, C.-Y.; Wang, T.-L.; Wang, C.-C. Functional Substitution of a Eukaryotic Glycyl-tRNA Synthetase with an Evolutionarily Unrelated Bacterial Cognate Enzyme. PLoS ONE 2014, 9, e94659. [Google Scholar] [CrossRef][Green Version]
  53. Vester, A.; Velez-Ruiz, G.; McLaughlin, H.M.; Program, N.C.S.; Lupski, J.R.; Talbot, K.; Vance, J.M.; Züchner, S.; Roda, R.H.; Fischbeck, K.H.; et al. A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. Hum. Mutat. 2012, 34, 191–199. [Google Scholar] [CrossRef] [PubMed]
  54. Zimon, M.; Baets, J.; Almeida-Souza, L.; De Vriendt, E.; Nikodinović, J.; Parman, Y.; Battaloǧlu, E.; Matur, Z.; Guergueltcheva, V.; Tournev, I.; et al. Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat. Genet. 2012, 44, 1080–1083. [Google Scholar] [CrossRef] [PubMed]
  55. Kachroo, A.H.; Laurent, J.M.; Yellman, C.M.; Meyer, A.; Wilke, C.O.; Salemi, M. Systematic humanization of yeast genes reveals conserved functions and genetic modularity. Science 2015, 348, 921–925. [Google Scholar] [CrossRef] [PubMed]
  56. Hamza, A.; Tammpere, E.; Kofoed, M.; Keong, C.; Chiang, J.; Giaever, G.; Nislow, C.; Hieter, P. Complementation of Yeast Genes with Human Genes as an Experimental Platform for Functional Testing of Human Genetic Variants. Genetics 2015, 201, 1263–1274. [Google Scholar] [CrossRef]
  57. Trott, A.; Morano, K. SYM1 Is the Stress-Induced Saccharomyces cerevisiae Ortholog of the Mammalian Kidney Disease Gene Mpv17 and Is Required for Ethanol Metabolism and Tolerance during Heat Shock. Eukaryot. Cell 2004, 3, 620–631. [Google Scholar] [CrossRef][Green Version]
  58. Nolli, C.; Goffrini, P.; Lazzaretti, M.; Zanna, C.; Vitale, R.; Lodi, T.; Baruffini, E. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy. Mitochondrion 2015, 25, 38–48. [Google Scholar] [CrossRef]
  59. Qian, Y.; Kachroo, A.H.; Yellman, C.M.; Salemi, M.; Johnson, K.A. Yeast Cells Expressing the Human Mitochondrial DNA Polymerase Reveal Correlations between Polymerase Fidelity and Human Disease Progression. J. Biol. Chem. 2014, 289, 5970–5985. [Google Scholar] [CrossRef]
  60. Suzuki, H.; Kanekura, K.; Levine, T.P.; Kohno, K.; Olkkonen, V.M.; Aiso, S.; Matsuoka, M. ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB. J. Neurochem. 2009, 108, 973–985. [Google Scholar] [CrossRef]
  61. Takata, T.; Kimura, Y.; Ohnuma, Y.; Kawawaki, J.; Kakiyama, Y.; Tanaka, K.; Kakizuka, A. Rescue of growth defects of yeast cdc48 mutants by pathogenic IBMPFD-VCPs. J. Struct. Biol. 2012, 179, 93–103. [Google Scholar] [CrossRef][Green Version]
  62. Wakasugi, K.; Quinn, C.L.; Tao, N.; Schimmel, P. Genetic code in evolution: Switching species-specific aminoacylation with a peptide transplant. EMBO J. 1998, 17, 297–305. [Google Scholar] [CrossRef]
  63. Eggermann, K.; Gess, B.; Hausler, M.; Weiß, J.; Hahn, A.; Kurth, I. Hereditary Neuropathies. Dtsch. Aerzteblatt Online 2018, 115, 91–97. [Google Scholar] [CrossRef]
  64. GeneCards. Available online: http://www.genecards.org/ (accessed on 12 May 2020).
  65. Penkett, C.J.; Morris, J.A.; Wood, V.; Bahler, J. YOGY: A web-based, integrated database to retrieve protein orthologs and associated Gene Ontology terms. Nucleic Acids Res. 2006, 34, W330–W334. [Google Scholar] [CrossRef]
  66. Uniprot Data Base. Available online: http://www.uniprot.org/ (accessed on 12 May 2020).
  67. Online Mendelian Inheritance in Man OMIM. Available online: https://omim.org/ (accessed on 12 May 2020).
  68. Wallen, R.C.; Antonellis, A. To charge or not to charge: Mechanistic insights into neuropathy-associated tRNA synthetase mutations. Curr. Opin. Genet. Dev. 2013, 23, 302–309. [Google Scholar] [CrossRef] [PubMed]
  69. Antonellis, A.; Ellsworth, R.E.; Sambuughin, N.; Puls, I.; Abel, A.; Lee-Lin, S.-Q.; Jordanova, A.; Kremensky, I.; Christodoulou, K.; Middleton, L.T.; et al. Glycyl tRNA Synthetase Mutations in Charcot-Marie-Tooth Disease Type 2D and Distal Spinal Muscular Atrophy Type V. Am. J. Hum. Genet. 2003, 72, 1293–1299. [Google Scholar] [CrossRef] [PubMed]
  70. Jordanova, A.; Irobi, J.; Thomas, F.P.; Van Dijck, P.; Meerschaert, K.; Dewil, M.; Dierick, I.; Jacobs, A.; De Vriendt, E.; Guergueltcheva, V.; et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat. Genet. 2006, 38, 197–202. [Google Scholar] [CrossRef] [PubMed]
  71. Latour, P.; Thauvin-Robinet, C.; Baudelet-Méry, C.; Soichot, P.; Cusin, V.; Faivre, L.; Locatelli, M.-C.; Mayençon, M.; Sarcey, A.; Broussolle, E.; et al. A Major Determinant for Binding and Aminoacylation of tRNAAla in Cytoplasmic Alanyl-tRNA Synthetase Is Mutated in Dominant Axonal Charcot-Marie-Tooth Disease. Am. J. Hum. Genet. 2010, 86, 77–82. [Google Scholar] [CrossRef]
  72. Gonzalez, M.; McLaughlin, H.; Houlden, H.; Guo, M.; Yo-Tsen, L.; Hadjivassilious, M.; Speziani, F.; Yang, X.-L.; Antonellis, A.; Reilly, M.M.; et al. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J. Neurol. Neurosurg. Psychiatry 2013, 84, 1247–1249. [Google Scholar] [CrossRef]
  73. Tsai, P.-C.; Soong, B.-W.; Mademan, I.; Huang, Y.-H.; Liu, C.-R.; Hsiao, C.-T.; Wu, H.-T.; Liu, T.-T.; Liu, Y.-T.; Tseng, Y.-T.; et al. A recurrent WARS mutation is a novel cause of autosomal dominant distal hereditary motor neuropathy. Brain 2017, 140, 1252–1266. [Google Scholar] [CrossRef] [PubMed]
  74. Harrower, T.; Stewart, J.D.; Hudson, G.; Houlden, H.; Warner, G.; O’Donovan, D.G.; Findlay, L.J.; Taylor, R.W.; De Silva, R.; Chinnery, P.F. POLG1 Mutations Manifesting as Autosomal Recessive Axonal Charcot-Marie-Tooth Disease. Arch. Neurol. 2008, 65, 133–136. [Google Scholar] [CrossRef] [PubMed]
  75. Baruffini, E.; Lodi, T.; Dallabona, C.; Puglisi, A.; Zeviani, M.; Ferrero, I. Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive external ophthalmoplegia in humans. Hum. Mol. Genet. 2006, 15, 2846–2855. [Google Scholar] [CrossRef] [PubMed]
  76. Baruffini, E.; Ferrero, I.; Foury, F. Mitochondrial DNA defects in Saccharomyces cerevisiae caused by functional interactions between DNA polymerase gamma mutations associated with disease in human. Biochim. Biophys. Acta 2007, 1772, 1225–1235. [Google Scholar] [CrossRef] [PubMed][Green Version]
  77. Baruffini, E.; Horvath, R.; Dallabona, C.; Czermin, B.; Lamantea, E.; Bindoff, L.A.; Invernizzi, F.; Ferrero, I.; Zeviani, M.; Lodi, T. Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model. Mitochondrion 2011, 11, 182–190. [Google Scholar] [CrossRef] [PubMed]
  78. Baruffini, E.; Ferrari, J.; Dallabona, C.; Donnini, C.; Lodi, T. Polymorphisms in DNA polymerase γ affect the mtDNA stability and the NRTI-induced mitochondrial toxicity in Saccharomyces cerevisiae. Mitochondrion 2014, 20, 52–63. [Google Scholar] [CrossRef] [PubMed]
  79. Lodi, T.; Dallabona, C.; Nolli, C.; Goffrini, P.; Donnini, C.; Baruffini, E. DNA polymerase γ and disease: What we have learned from yeast. Front. Genet. 2015, 6, 106. [Google Scholar] [CrossRef]
  80. Stuart, G.R.; Santos, J.H.; Strand, M.K.; Van Houten, B.; Copeland, W.C. Mitochondrial and nuclear DNA defects in Saccharomyces cerevisiae with mutations in DNA polymerase γ associated with progressive external ophthalmoplegia. Hum. Mol. Genet. 2005, 15, 363–374. [Google Scholar] [CrossRef]
  81. Kaliszewska, M.; Kruszewski, J.; Kierdaszuk, B.; Kostera-Pruszczyk, A.; Nojszewska, M.; Łusakowska, A.; Vizueta, J.; Sabat, D.; Lutyk, D.; Lower, M.; et al. Yeast model analysis of novel polymerase gamma variants found in patients with autosomal recessive mitochondrial disease. Qual. Life Res. 2015, 134, 951–966. [Google Scholar] [CrossRef]
  82. Stuppia, G.; Rizzo, F.; Riboldi, G.; Del Bo, R.; Nizzardo, M.; Simone, C.; Comi, G.P.; Bresolin, N.; Corti, S. MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives. J. Neurol. Sci. 2015, 356, 7–18. [Google Scholar] [CrossRef]
  83. Filadi, R.; Pendin, D.; Pizzo, P. Mitofusin 2: From functions to disease. Cell Death Dis. 2018, 9, 330. [Google Scholar] [CrossRef]
  84. Amiott, E.A.; Cohen, M.M.; Saint-Georges-Chaumet, Y.; Weissman, A.M.; Shaw, J.M. A Mutation Associated with CMT2A Neuropathy Causes Defects in Fzo1 GTP Hydrolysis, Ubiquitylation, and Protein Turnover. Mol. Biol. Cell 2009, 20, 5026–5035. [Google Scholar] [CrossRef]
  85. Vallese, F.; Barazzuol, L.; Maso, L.; Brini, M.; Calí, T. ER-Mitochondria Calcium Transfer, Organelle Contacts and Neurodegenerative Diseases. Adv. Exp. Med. Biol. 2020, 1131, 719–746. [Google Scholar] [CrossRef]
  86. De Mario, A.; Quintana-Cabrera, R.; Martinvalet, D.; Giacomello, M. (Neuro) degenerated Mitochondria-ER contacts. Biochem. Biophys. Res. Commun. 2017, 483, 1096–1109. [Google Scholar] [CrossRef] [PubMed]
  87. Erpapazoglou, Z.; Mouton-Liger, F.; Corti, O. From dysfunctional endoplasmic reticulum-mitochondria coupling to neurodegeneration. Neurochem. Int. 2017, 109, 171–183. [Google Scholar] [CrossRef] [PubMed]
  88. Krols, M.; Van Isterdael, G.; Asselbergh, B.; Kremer, A.; Lippens, S.; Timmerman, V.; Janssens, S. Mitochondria-associated membranes as hubs for neurodegeneration. Acta Neuropathol. 2016, 131, 505–523. [Google Scholar] [CrossRef] [PubMed]
  89. Rzepnikowska, W.; Flis, K.; Muñoz-Braceras, S.; Menezes, R.; Escalante, R.; Zoladek, T. Yeast and other lower eukaryotic organisms for studies of Vps13 proteins in health and disease. Traffic 2017, 18, 711–719. [Google Scholar] [CrossRef] [PubMed]
  90. Gomez-Suaga, P.; Paillusson, S.; Stoica, R.; Noble, W.; Hanger, D.P.; Miller, C.C.J. The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy. Curr. Biol. 2017, 27, 371–385. [Google Scholar] [CrossRef]
  91. Szymański, J.; Janikiewicz, J.; Michalska, B.; Patalas-Krawczyk, P.; Perrone, M.; Ziółkowski, W.; Duszynski, J.; Pinton, P.; Dobrzyń, A.; Wieckowski, M.R. Interaction of Mitochondria with the Endoplasmic Reticulum and Plasma Membrane in Calcium Homeostasis, Lipid Trafficking and Mitochondrial Structure. Int. J. Mol. Sci. 2017, 18, 1576. [Google Scholar] [CrossRef]
  92. Balla, T.; Kim, Y.J.; Alvarez-Prats, A.; Pemberton, J. Lipid Dynamics at Contact Sites between the Endoplasmic Reticulum and Other Organelles. Annu. Rev. Cell Dev. Biol. 2019, 35, 85–109. [Google Scholar] [CrossRef]
  93. González-Sánchez, P.; Satrústegui, J.; Palau, F.; Del Arco, A. Calcium Deregulation and Mitochondrial Bioenergetics in GDAP1-Related CMT Disease. Int. J. Mol. Sci. 2019, 20, 403. [Google Scholar] [CrossRef]
  94. Rencus-Lazar, S.; DeRowe, Y.; Adsi, H.; Gazit, E.; Laor, D. Yeast Models for the Study of Amyloid-Associated Disorders and Development of Future Therapy. Front. Mol. Biosci. 2019, 6, 15. [Google Scholar] [CrossRef]
  95. Griffioen, G.; Duhamel, H.; Van Damme, N.; Pellens, K.; Zabrocki, P.; Pannecouque, C.; Van Leuven, F.; Winderickx, J.; Wera, S. A yeast-based model of α-synucleinopathy identifies compounds with therapeutic potential. Biochim. Biophys. Acta 2006, 1762, 312–318. [Google Scholar] [CrossRef]
  96. Tardiff, D.F.; Jui, N.T.; Khurana, V.; Tambe, M.A.; Thompson, M.L.; Chung, C.Y.; Kamadurai, H.; Kim, H.T.; Lancaster, A.K.; Caldwell, K.A.; et al. Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates -Synuclein Toxicity in Neurons. Science 2013, 342, 979–983. [Google Scholar] [CrossRef] [PubMed]
  97. Dajas, F.; Rivera, F.; Blasina, F.; Arredondo, F.; Echeverry, C.; Lafon, L.; Morquio, A.; Heizen, H. Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox. Res. 2003, 5, 425–432. [Google Scholar] [CrossRef] [PubMed]
  98. Chung, C.Y.; Khurana, V.; Auluck, P.K.; Tardiff, D.F.; Mazzulli, J.R.; Soldner, F.; Baru, V.; Lou, Y.; Freyzon, Y.; Cho, S.; et al. Identification and Rescue of -Synuclein Toxicity in Parkinson Patient-Derived Neurons. Science 2013, 342, 983–987. [Google Scholar] [CrossRef] [PubMed]
  99. Estela, A.; Pla-Martín, D.; Sánchez-Piris, M.; Sesaki, H.; Palau, F. Charcot-Marie-Tooth-related Gene GDAP1 Complements Cell Cycle Delay at G2/M Phase in Saccharomyces cerevisiae fis1 Gene-defective Cells. J. Biol. Chem. 2011, 286, 36777–36786. [Google Scholar] [CrossRef]
  100. Rzepnikowska, W.; Kaminska, J.; Kabzińska, D.; Kochański, A. Pathogenic Effect of GDAP1 Gene Mutations in a Yeast Model. Genes 2020, 11, 310. [Google Scholar] [CrossRef]
  101. Vaccari, I.; Dina, G.; Tronchere, H.; Kaufman, E.; Chicanne, G.; Cerri, F.; Wrabetz, L.; Payrastre, B.; Quattrini, A.; Weisman, L.S.; et al. Genetic Interaction between MTMR2 and FIG4 Phospholipid Phosphatases Involved in Charcot-Marie-Tooth Neuropathies. PLoS Genet. 2011, 7, e1002319. [Google Scholar] [CrossRef]
  102. D’Antonio, M.; Musner, N.; Scapin, C.; Ungaro, D.; Del Carro, U.; Ron, D.; Feltri, M.L.; Wrabetz, L. Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice. J. Exp. Med. 2013, 210, 821–838. [Google Scholar] [CrossRef]
  103. Harding, H.P.; Novoa, I.; Zhang, Y.; Zeng, H.; Wek, R.; Schapira, M.; Ron, D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 2000, 6, 1099–1108. [Google Scholar] [CrossRef]
  104. Baker, N.C.; Ekins, S.; Williams, A.J.; Tropsha, A. A bibliometric review of drug repurposing. Drug Discov. Today 2018, 23, 661–672. [Google Scholar] [CrossRef]
  105. Rak, M.; Tetaud, E.; Godard, F.; Sagot, I.; Salin, B.; Duvezin-Caubet, S.; Slonimski, P.P.; Rytka, J.; Di Rago, J.-P. Yeast Cells Lacking the Mitochondrial Gene Encoding the ATP Synthase Subunit 6 Exhibit a Selective Loss of Complex IV and Unusual Mitochondrial Morphology. J. Biol. Chem. 2007, 282, 10853–10864. [Google Scholar] [CrossRef]
  106. Rak, M.; Tetaud, E.; Duvezin-Caubet, S.; Ezkurdia, N.; Bietenhader, M.; Rytka, J.; Di Rago, J.-P. A Yeast Model of the Neurogenic Ataxia Retinitis Pigmentosa (NARP) T8993G Mutation in the Mitochondrial ATP Synthase-6 Gene. J. Biol. Chem. 2007, 282, 34039–34047. [Google Scholar] [CrossRef] [PubMed]
  107. Schwimmer, C.; Rak, M.; Lefebvre-Legendre, L.; Duvezin-Caubet, S.; Plane, G.; Di Rago, J.-P. Yeast models of human mitochondrial diseases: From molecular mechanisms to drug screening. Biotechnol. J. 2006, 1, 270–281. [Google Scholar] [CrossRef] [PubMed]
  108. Oliveira, A.V.; Vilaça, R.; Costa, V.; Menezes, R.; Santos, C. Exploring the power of yeast to model aging and age-related neurodegenerative disorders. Biogerontology 2016, 18, 3–34. [Google Scholar] [CrossRef] [PubMed]
  109. Soma, S.; Latimer, A.J.; Chun, H.; Vicary, A.C.; Timbalia, S.A.; Boulet, A.; Rahn, J.J.; Chan, S.S.L.; Leary, S.; Kim, B.-E.; et al. Elesclomol restores mitochondrial function in genetic models of copper deficiency. Proc. Natl. Acad. Sci. USA 2018, 115, 8161–8166. [Google Scholar] [CrossRef] [PubMed]
  110. McGary, K.L.; Park, T.J.; Woods, J.O.; Cha, H.J.; Wallingford, J.B.; Salemi, M. Systematic discovery of nonobvious human disease models through orthologous phenotypes. Proc. Natl. Acad. Sci. USA 2010, 107, 6544–6549. [Google Scholar] [CrossRef]
  111. Lehner, B. Genotype to phenotype: Lessons from model organisms for human genetics. Nat. Rev. Genet. 2013, 14, 168–178. [Google Scholar] [CrossRef] [PubMed]

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
Neuronal Reprogramming for Tissue Repair and Neuroregeneration
Previous
Overexpression of Isoprene Synthase Affects ABA- and Drought-Related Gene Expression and Enhances Tolerance to Abiotic Stress
Next